Monte Rosa Therapeutics Files 2025 Proxy Statement
Ticker: GLUE · Form: DEF 14A · Filed: Apr 25, 2025 · CIK: 1826457
| Field | Detail |
|---|---|
| Company | Monte Rosa Therapeutics, Inc. (GLUE) |
| Form Type | DEF 14A |
| Filed Date | Apr 25, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, shareholder-meeting, governance
TL;DR
Monte Rosa filed its proxy statement for 2024. Get ready to vote.
AI Summary
Monte Rosa Therapeutics, Inc. filed its definitive proxy statement on April 25, 2025, for the fiscal year ending December 31, 2024. The company, located at 321 Harrison Avenue, Suite 900, Boston, MA, is involved in the biological products sector. This filing is a standard proxy statement, indicating it's related to shareholder matters and annual meetings.
Why It Matters
This filing provides shareholders with essential information regarding upcoming votes and company governance, allowing them to make informed decisions about their investments.
Risk Assessment
Risk Level: low — This is a routine DEF 14A filing, a standard proxy statement for shareholder meetings, and does not contain new material financial or operational information.
Key Players & Entities
- Monte Rosa Therapeutics, Inc. (company) — Registrant
- 321 Harrison Avenue, Suite 900, Boston, MA 02118 (address) — Company Business Address
FAQ
What is the purpose of this DEF 14A filing?
This filing is a definitive proxy statement filed by Monte Rosa Therapeutics, Inc. pursuant to Section 14(a) of the Securities Exchange Act of 1934, providing information to shareholders for an upcoming meeting.
When is the fiscal year end for Monte Rosa Therapeutics?
The fiscal year end for Monte Rosa Therapeutics is December 31.
What is the company's Standard Industrial Classification (SIC) code?
The SIC code for Monte Rosa Therapeutics is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Where is Monte Rosa Therapeutics headquartered?
Monte Rosa Therapeutics is headquartered at 321 Harrison Avenue, Suite 900, Boston, MA 02118.
What is the filing date of this proxy statement?
This definitive proxy statement was filed on April 25, 2025.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 25, 2025 regarding Monte Rosa Therapeutics, Inc. (GLUE).